EP Patent

EP3126367A1 — Polymorphic mixture of rifaximin and its use for the preparation of solid formulations

Assigned to Archimica SpA · Expires 2017-02-08 · 9y expired

What this patent protects

A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15 ± 3 and a process for its preparation are herein disclosed. Said polymorphic mixture of Rifaximin is also disclosed for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic …

USPTO Abstract

A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15 ± 3 and a process for its preparation are herein disclosed. Said polymorphic mixture of Rifaximin is also disclosed for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprising said polymorphic mixture of Rifaximin as active ingredient, in particular a solid formulation, more in particular a film coated tablet are disclosed. A polymorphic form of crude wet rifaximin and of purified wet rifaximin and their use as intermediates in a process for the preparation of Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15 ± 3 are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3126367A1
Jurisdiction
EP
Classification
Expires
2017-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Archimica SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.